H eart failure (HF) is a leading cause of hospitalization in older adults. 1 Nearly 80% of HF costs are due to hospitalizations and readmissions, which reduce quality of life (QOL) and are independently associated with death. 2 In a retrospective chart review, approximately 40% of early readmissions following HF hospitalization were related to suboptimal transitional care (ie, actions that promote care coordination and continuity as patients transfer between health care settings). 3, 4 In an observational study, patients discharged from hospitals with the lowest 1-week follow-up rates experienced the highest 30-day readmission rates. 5 Transitional care services can improve outcomes, but have not been systematically implemented. A network metaanalysis of randomized clinical trials (RCTs) was undertaken to inform the design of a transitional care model. 6 Nurse-led home visits and multidisciplinary heart function clinics (HFCs) were associated with a reduction in all-cause readmissions and death relative to other services following hospitalization for HF, with benefits evident within 30 days of discharge. 7 Shared features included self-care education and multidisciplinary care. 6 In an effort to translate knowledge to action, 8 evidenceinformed services 6 were combined with guideline recommendations 9 ,10 and a patient-centered approach 11, 12 to form the Patient-Centered Care Transitions in HF (PACT-HF) service model. With an integrated knowledge translation research approach 13 and a pragmatic stepped-wedge cluster randomized trial design for sequential implementation across hospitals, 14, 15 this study tested the effect of the intervention on a composite outcome of all-cause readmission, emergency department (ED) visit, or death at 3 months and allcause readmission or ED visit at 30 days.
Methods
The protocol and statistical analysis plan are included in Supplement 1 and Supplement 2. 16 Because services were evidence-informed and considered quality improvement, 6,7 the study was approved by all institutional research ethics boards with waiver of written consent. Patients provided verbal informed consent for study participation. We considered 11 tertiary or quaternary care urban hospitals across southern Ontario for inclusion. We excluded 1 hospital corporation that could not agree to a randomized implementation sequence. We incorporated feedback from patients, clinicians, and policy makers during the planning phase.
16,17

Patients
We included patients whose primary reason for hospitalization was HF. We excluded patients who did not have HF, did not consent to inclusion, died during hospitalization, were transferred to another hospital, or were discharged with a primary diagnosis other than HF. During the intervention phase, Boston criteria 18 and/or serum thresholds of brain natriuretic peptide (BNP) or N-terminal prohormone brain natriuretic peptide were used to exclude a diagnosis of HF (eFigure 1 in Supplement 3).
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Randomization
Using a stepped-wedge design, we introduced the intervention to 10 hospitals in a randomized sequence, determined by a number generator, at monthly intervals until all hospitals received the intervention (eFigure 2 in Supplement 3). 16 We measured clinical outcomes in each hospital during the baseline month. We remeasured outcomes whenever a hospital crossed over from usual care to the intervention, making within-and between-hospital comparisons. We measured secondary outcomes in a nested sample of 8 hospitals. The study domains were pragmatic (eFigure 3 in Supplement 3), designed to assess effectiveness rather than efficacy. 16 
Intervention
For hospitals undergoing the intervention, a hospital nurse navigator provided the following at the time of discharge: (1) a needs assessment based on the patient's self-reported QOL, 20 in addition to multidisciplinary referrals (eg, physiotherapy) as needed; (2) HF self-care education 21 to the patient and informal caregiver; (3) a structured patientcentered discharge summary with a symptom-driven action plan to the patient and the family physician; (4) family physician follow-up arrangements within 1 week of discharge; and (5) referrals to postdischarge nurse-led home visits and HFC care for patients with length of stay, acuity of presentation, comorbidities, and ED visits in the preceding 6 months (LACE index) 22 ,23 of at least 13 (eFigure 1 in Supplement 3). The nurse-led visits included weekly, structured, face-to-face and telephone assessments lasting 4 to 6 weeks until patients were seen in the HFC. In the event of deterioration, the home-care nurse helped the patient follow the discharge action plan and contacted the HFC for expedited care. HF guidelines 9 were distributed, but management was left to clinicians' discretion. In the usual care group, transitional care occurred at the discretion of clinicians. In 1 hospital, a nurse provided education and a home visit to select patients. Eight hospitals had access to regional HFCs, while 2 did not.
Outcomes
Primary clinical outcomes were hierarchically ordered as time to first composite all-cause readmission, ED visit, or death at 3 months and all-cause readmission or ED visit at 30 days among patients.
Secondary patient-reported outcomes were the B-PREPARED score for discharge preparedness 24 at 6 weeks (range: 0-22; a higher score indicates higher level of preparedness); the 3-Item Care Transitions Measure (CTM-3) 25 score for quality of care transition at 6 weeks (range: 0-100; a higher score indicates a higher quality of care); the 5-level EQ-5D version (EQ-5D-5L) 26 scores for QOL at discharge, 6 weeks, and 6 months (range: 0-1; 0 indicates dead and 1 indicates full health); and quality-adjusted life-years (QALY), 27 a measure of life span weighted by EQ-5D-5L health utilities, 26 at 6 months (range: 0-0.5; 0 indicates dead and, for this study, 0.5 indicates full health at 6 months). While minimally important differences have not been established for the B-PREPARED and CTM-3 scores, a mean (SD) difference of 0.037 (0.001) in EQ-5D-5L is considered clinically relevant.
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Standard scripts were used for the surveys. Secondary health care cost outcomes will be reported separately. Post hoc exploratory clinical outcomes included individual components of the composite clinical outcomes at 3 months and 30 days, as well as number of clinical events at 3 months and 30 days. In a post hoc sensitivity analysis, we reassessed the effect of the intervention on the primary composite clinical outcomes among all patients hospitalized with HF and discharged alive at participating hospitals during the study, as identified in administrative databases. 16 All outcomes were measured relative to the discharge date of the index HF hospitalization, defined as the first unplanned hospitalization for HF in a participating hospital during the study period. 16 To identify the cohort for analysis, 16 we used the Canadian Institute for Health Information database accessed at the Institute for Clinical Evaluative Sciences (ICES).
For the main analysis, eligible intervention patients identified prospectively in the hospital were matched to a comparator group identified in the database with propensity scores of at least 0.4, derived using logistic regression with the stepwise selection of the following variables: age, sex, admission through the ED, length of stay greater than 2 days, and presence of diabetes, chronic kidney disease, myocardial infarction, or atrial fibrillation. We obtained linkages to databases (eTable 1 in Supplement 3) using unique encoded identifiers accessed and analyzed at ICES.
Sample Size
Assuming 320 patients per cluster, a 0.01 intraclass correlation coefficient, and a 28% composite 1-year event rate, we expected 80% statistical power (2-sided P < .05) to detect a 25% change in primary outcomes (10 clusters) and 90% power to detect a 5% change in patient-reported outcomes (8  clusters) . 16, 29, 30 The 25% target in primary outcomes was based on the proportion of readmissions estimated to be preventable, 3, 31 as well as the anticipated risk reduction of services included in the transitional care model based on systematic reviews.
6,7
Statistical Analysis
The unit of analysis was patients, analyzed according to their allocated group regardless of treatment received. Data were summarized using mean (SD) and median (interquartile range [IQR]) for continuous variables, and counts with percentages for categorical variables. Baseline variables were compared using the standardized difference with a significant threshold of 0.10. A 2-sided P < .05 significance threshold was used for all analyses. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as exploratory.
Regression models for all primary and secondary outcomes were adjusted for the stepped-wedge design, with the intervention and steps (time) as fixed effects and hospitals as random effects. We analyzed primary clinical outcomes using shared frailty survival models nested within hospitals, with a fixed-sequence procedure for sequentially testing hierarchical clinical outcomes; if the first null hypothesis in the hierarchy was not rejected at a nominal level of 5%, the second hypothesis was tested as an exploratory analysis. 29 We plotted Kaplan-Meier curves for the primary outcomes. We described effects on survival and count outcomes using hazard ratio (HR) and relative risk (RR), respectively, with 95% CIs. We tested the proportionality assumptions for the primary outcomes using the Kolmogorov-type supremum test; the assumptions were not violated. We used Poisson regression to analyze the number of events among surviving patients. We tested for between-hospital heterogeneity in the intervention's effect on primary outcomes in a post hoc analysis by computing the HR with 95% CI at each hospital and using the type III test (shared frailty survival models).
We measured the effect of the intervention on B-PREPARED, CTM-3, and EQ-5D-5L using generalized linear mixed models, reporting mean differences and 95% CIs. We imputed missing data for living patients using age, sex, and LACE score; we used the Markov chain Monte Carlo method and assumed that all the variables followed a joint multivariate normal distribution. We imputed missing EQ-5D-5L scores at either 6 weeks or 6 months if baseline and 1 of 2 follow-up measures were collected. We calculated QALY using the area-under-thecurve approach with EQ-5D-5L-derived utilities and corresponding survival duration. 27 We analyzed the intervention's effect on QALY using mixed linear regression, adjusting for discharge EQ-5D-5L. We conducted all analyses using SAS version 9.4 for UNIX (SAS Institute).
Results
Hospitals
The 10 clusters included in the analysis were urban tertiary or quaternary care hospitals with onsite cardiologists, cardiac critical care units, and cardiac imaging facilities; 5 had cardiac catheterization laboratories and 3 offered cardiac surgery onsite. All had onsite or regional HFCs during the intervention phase.
Patients
Patients were enrolled from February 1, 2015, to March 30, 2016 ( Figure 1) . Among 2494 eligible patients included in the primary analysis (1104 receiving the intervention and 1390 receiving usual care), the mean (SD) age was 77.7 (12.1) years, 1258 (50.4%) were women, 2488 (99.8%) were admitted to the hospital via the ED, and 706 (28.3%) had at least 3 ED visits in the preceding 6 months. Mean (SD) length of hospital stay was 7.7 (5.6) days. The intervention and usual care groups were similar in baseline demographics, QOL, comorbidities, estimated prognosis based on the Charlson 32 index, and health care utilization based on length of stay and mean resource intensity weights 33 during the index hospitalization (standardized difference ≤0.10, Table 1 ). While the median resource intensity weights were the same in both groups, the standardized difference was 0.20. Characteristics of the groups prior to propensity matching are presented in eTable 2 in Supplement 3. Based on 2140 patients whose drug administrative data were available, there was no significant difference between the intervention and usual care groups in the proportion that filled postdischarge prescriptions for angiotensin-converting enzyme inhibitors, β-blockers, mineralocorticoid receptor antagonists, or diuretics at 7 days (82.5% vs 79.8%; P = .11) or 30 days (92.8% vs 92.7%: P = .95).
Intervention Fidelity
Retrospective administrative data revealed that 2525 patients were hospitalized with HF during the intervention phase; however, only 2192 (86.8%) were screened for eligibility while in the hospital, indicating that at least 13.2% of patients were missed. Of 1043 patients in the intervention group for whom information was available, 916 (87.8%) had a discharge summary faxed to their family physician within a day of discharge. Among the 1104 patients in the intervention group, 485 (43.9%) had a LACE index of at least 13 on the day of Figure 2 ). Because there was no significant between-group difference in the first primary outcome in the hierarchy, analysis on the second co-primary outcome was considered exploratory. (Figure 3 ).
Secondary Patient-Reported Outcomes
We collected patient-reported data from 986 patients across 8 hospitals ( In an unadjusted before-and-after exploratory analysis, there were significant associations between the intervention group and first primary outcome of time to first composite allcause readmission, ED visit, or death at 3 months at 2 of 10 hospitals (eFigure 6 in Supplement 3). However, no statistically significant between-hospital heterogeneity was found in the effect of the intervention on the primary composite outcomes at 3 months (P = .06) and 30 days (P = .07) when accounting for the stepped-wedge design.
Among 2247 patients (993 in the intervention and 1254 in the usual care group) alive at 3 months, there was no significant difference between the intervention and usual care group, respectively, in the number of composite all-cause readmissions or ED visits ( Outcomes are measured relative to the date of hospital discharge following index hospitalization for heart failure, with patients analyzed in their allocated treatment group. Median (interquartile range) days of follow-up was 30 (30-30) for the intervention and usual care groups.
Research Original Investigation
Effect In the post hoc sensitivity analysis of all patients hospitalized for HF during the study period (2525 in the intervention and 1918 in the usual care group), there was no significant difference between the intervention and usual care groups in the primary composite outcomes at 3 months (incidence, 51.6% vs 51.8%; HR, 1.00 [95% CI, 0.88-1.15]; P = .93)or30days (incidence, 31.1% vs 32.1%; HR, 0.91 [95% CI, 0.76-1.09]; P = .32).
Discussion
In this pragmatic stepped-wedge cluster randomized trial, a patient-centered transitional care model did not improve time to first all-cause readmission, ED visit, or death at 3 months or time to first all-cause readmission or ED visit at 30 days following HF hospitalization.
An implication of these results is that health services with demonstrated efficacy in explanatory RCTs may not be effective in improving clinical outcomes when implemented at the level of the health care system. Unlike explanatory RCTs, this pragmatic trial used broad eligibility criteria and included patients regardless of age, left ventricular function, comorbidities, or prognosis. The trial included patients without a fixed address, patients who are homebound or reside in nursing homes, and patients with language differences and suboptimal health literacy or self-care. The trial population, which was older and had a higher prevalence of comorbid conditions than populations in a majority of published transitional care RCTs, 6, 7 represents patients in health care settings who are often excluded from RCTs 28 because of anticipated nonadherence, barriers to care, or illnesses that decrease an intervention's efficacy. This trial involved multicenter recruitment that included both tertiary and quaternary care centers and use of personnel managed by their institutions rather than by the research team; it is possible that this pragmatic approach introduced variation between hospitals and modified the intervention's effect. For example, while there was no statistically significant heterogeneity in the effect of the intervention on the primary composite outcomes across hospitals, exploratory beforeand-after analysis revealed significant associations between the intervention and the first primary composite outcome in 2 of the 10 hospitals.
Another reason that results may have diverged from past clinical trials is that services were titrated to risk. Nurse-led home visits and HFC care were offered to less than 40% of the intervention group, which may have diluted the effect of these interventions. The neutral findings may also represent a floor effect among high-risk patients who are at a more advanced disease stage and face a higher proportion of unavoidable admissions than low-risk patients. 1 An additional pitfall of using risk prediction to guide resource allocation is that risk models are not always reliable. While the LACE index is a simple tool, validated for risk prediction at the bedside, its ability to discriminate risk in HF is modest.
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Health services often depend on contextual factors for delivery and uptake. 30, 33 Just before this trial, Ontario introduced a funding incentive for hospitals to improve quality of care and reduce readmissions in HF
10
; while this facilitated engagement of policy makers in the research, it may have also motivated hospitals to improve baseline health care quality, thereby producing a ceiling effect and minimizing the benefit of the intervention.
This study was designed to detect a 25% improvement in the first primary composite clinical outcome, arguably an Abbreviations: CTM-3, 3-Item Care Transitions Measure; EQ-5D-5L, 5-level EQ-5D version; QALY, quality-adjusted life-year.
a Least-square mean models are adjusted for the stepped-wedge design. The 6-week and 6-month EQ5D5L scores and QALYs are adjusted for discharge EQ-5D-5L scores.
b B-PREPARED score 24 is a measure of discharge preparedness, ranging from 0 (worst) to 22 (best). c CTM-3 25 is a measure for quality of care transition, ranging from 0 (worst) to 100 (best).
26 is a measure of quality of life based on domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from 0 (dead) to 1 (best quality of life).
e QALY, 27 a measure of both quantity and quality of life, is obtained by multiplying the value associated with a given state of health by the years lived in that state. All postdischarge measures were obtained via the telephone. A QALY of 1 implies perfect health for 1 year; QALY was measured over 6 months, so it is anchored at 0 (dead) and 0.5 (best health at 6 months).
Effect of Transitional Care Services on Outcomes Among Inpatients With Heart Failure
Original ambitious target, and the possibility that the intervention improved outcomes below this threshold of detection cannot be excluded. Findings of post hoc exploratory analyses were largely consistent with a nonsignificant difference in primary outcomes between the intervention and usual care groups.
Among the individual components of the primary composite clinical outcomes at 3 months and 30 days, a benefit in the intervention group was noted only in time to first ED visit at 30 days, with no reduction in number of readmissions or ED visits during the follow-up period. Health care interventions that do not improve clinical outcomes can improve outcomes that are meaningful to patients; this tension can pose a challenge to policy makers regarding program funding. The intervention improved the secondary outcomes of discharge preparedness, quality of care transition, and QOL, but these outcomes were exploratory, and the lack of improvement in QALY, which measures both quality and quantity of life, may indicate the need for stronger evidence to support funding this intervention.
This study has several strengths. Patients, clinicians, and policy makers were engaged in this work, and the selected outcomes were meaningful to patients and the health care system. The intervention was tested using a stepped-wedge design that is novel in cardiovascular research and less subject to bias than typical quality improvement research methods.
14, 15 In applying a pragmatic 6 approach and using existing resources within the publicly funded system, the study's results reflect effectiveness in clinical settings.
33,34
The use of administrative databases to measure clinical outcomes minimized measurement burden on patients, and the use of time-to-event analysis and nested substudies in the context of a stepped-wedge trial advanced the science of trial design.
Limitations
This study has several limitations. First, the clinical trial was confined to urban hospitals in a single-payer health care system, and results may not be generalizable to other health care systems. Second, while the baseline characteristics in the intervention and usual care groups were similar, there was a wider distribution of resource intensity weights, a measure of resource utilization, in the intervention group. Third, while certain process-of-care indicators were audited, the quality and duration of each episode of care and patients' adherence to discharge recommendations were not assessed. Fourth, improvements in usual care just prior to the onset of the trial cannot be excluded, and these improvements may have caused a ceiling effect. Fifth, while steps were taken to avoid contamination, uptake of the intervention during the usual care phase cannot be excluded. Sixth, the focus of services on high-risk patients with little modifiable risk may have produced a floor effect.
Conclusions
Among This protocol has been developed by the Principal Investigator and Co-Investigators and its contents are the intellectual property of this group. It is an offence to reproduce or use the information and data in this protocol for any purpose other than this trial without prior approval from the Principal Investigator. 
PACT-HF PROTOCOL SIGNATURE PAGE
Study Goal
The goal of the study is to determine whether the Patient-Centered Care Transitions in Heart Failure (PACT-HF) model will improve time-to-first composite all-cause Emergency Department (ED) visits, readmission, or death at 3 months and time-to-first composite allcause ED visits or readmission at 30 days compared to routine care for patients discharged after hospitalization for heart failure.
Study Objectives
Primary Aim:
To determine the effectiveness of PACT-HF in improving time to first event of (1) 3 month composite all-cause death, readmission, and ED visits and (2) 30-day composite all-cause readmission or ED visits.
Secondary Aim:
To determine the effectiveness of PACT-HF in: 1. Improving the patient-centered outcomes of Discharge Preparedness, Care Transitions Quality, Quality of Life (QOL), and Quality Adjusted Life Years (QALY). 2. Reducing 6-month health system costs in patients being discharged with HF.
Study Design
Multicenter stepped wedge (SW) cluster RCT in which the intervention will be introduced to hospitals over a number of time periods in a randomized sequence until all hospitals receive it. The outcomes will be measured at all hospitals prior to the intervention and whenever a new hospital (ÒstepÓ) receives the intervention. At each step, there will be a comparison of outcomes between the hospitals receiving the intervention and those not receiving it. Once assigned the intervention, a hospital will receive it for the remainder of the study.
Participants/Study Duration
Approximately 3500 participants will be enrolled over 2 years.
Study Population
Patients hospitalized with heart failure (HF)
Intervention ALL hospitalized patients with confirmed HF will receive the intervention. During the intervention phase at each hospital, a trained nurse case manager (NCM) will assess the patient within 1 business day of admission and work with the medical team to perform the following services: (1) comprehensive assessment, (2) Patient/Informal caregiver self-care education, (3) a patient-centered discharge summary, (4) Early post-discharge follow-up with the family physician and (5) Nurse-led home-care and multidisciplinary HF clinic referrals (for patients deemed high risk of readmission).
Evaluation Period for Outcome Events
Clinical Events outcomes will be measured at all participating hospitals prior to the intervention and whenever a new hospital (ÔstepÕ) receives the intervention. At each step there will be a comparison of clinical outcomes between hospitals and those not receiving it. Evaluation period will continue till all hospitals receive the intervention.
Assessment of Outcome Events
Process-of-care measures will be obtained from all hospitals at pre-specified intervals i n the intervention sites by a NCM and/or research assistant, using data in hospital administrative lists, case report forms, phone calls to the FPs, and records from Community Care Access Centres (CCAC). We will measure the primary and secondary outcomes across hospitals (1) at baseline (for 6 consecutive months preceding implementation) and (2) at each step (i.e. each month that PACT-HF is introduced to a new hospital). Patient-centered outcomes will be measured in a select group of hospitals only.
Statistical Methodology
We will analyze all outcomes using intention-to-treat principle. All statistical tests will be 2-tailed, with alpha = 0.05. We will use SAS 9.2 (Cary, NC) for analyses. At each step, we will compare the following outcomes in the hospitals receiving the intervention with those in hospitals receiving usual care within the given block. Primary Outcomes Time to first event of (1) 3 month composite all-cause death, readmission, and ED visits and (2) 30-day composite all-cause readmission or ED visits. Secondary outcomes (1) Discharge Preparedness, Care Transitions Measure (CTM), and Quality of Life, as measured by mean B-PREPARED score, mean CTM-3 score, and mean change in EQ-5D-5L scores, respectively. Quality Adjusted Life Years (QALY) will also be measured. (2) Health care cost, as measured by the 6-month mean medical cost per patient.
Date of Protocol
May 1, 2015 1.0 STUDY DESIGN We will perform a multicenter stepped wedge (SW) cluster RCT [1] [2] [3] in which the intervention will be introduced to several hospitals over a number of time periods in a randomized sequence until all hospitals receive it. The clinical outcomes will be measured at all hospitals prior to the intervention and whenever a new hospital (ÒstepÓ) receives the intervention. At each step, there will be a comparison of clinical outcomes between the hospitals receiving the intervention and those not to receiving it. Once assigned the intervention, a hospital will receive it for the remainder of the study. The effectiveness of PACT-HF on patientcentered outcomes will be explored across a select number of consecutive steps. Cost outcomes will be measured across all steps.
RANDOMIZATION OF HOSPITALS
The unit of randomization will be the hospital. Hospitals will be randomly assigned to initiate the intervention at either of steps 1 through 10.
DURATION OF INTERVENTION
We will introduce PACT-HF to a new hospital every month. A one-month interval between steps is expected to be feasible as the preparation of hospitals, CCACs, and HF clinics, and recruitment of personnel will occur during the six months preceding the first step. Once introduced to PACT-HF, hospitals will receive it for the remainder of the study. The intervention phase will continue until the hospital randomized to the last step has received it for 6 months.
1.3
PATIENTS Patients hospitalized with a most responsible diagnosis of HF will be identified daily through hospital admission databases and referrals from inpatient providers. Diagnosis of HF will be confirmed by the nurse case manager (NCM) using the validated Boston criteria 5 and/or BNP / NT-proBNP levels (which are specific for HF). Patients discharged to long-term care facilities will receive the intervention but will be excluded from CCAC home-care referrals.
INTERVENTION
The goal is for all hospitalized patients with confirmed HF to receive the intervention. At each hospital receiving PACT-HF, a trained NCM will assess the patient within 1 business day of admission and work with the medical team to perform the following services. (1) Comprehensive assessment of the patientÕs clinical status and social supports. (2) Patient/ Informal caregiver (iCG) self-care education, with a focus on symptom-recognition and behavioral responses to maintain disease stability. The education session(s) will be guided by a previously validated set of tools.
6,7 (3) A patient-centered discharge summary, given to the patient / iCG and faxed to the family physician (FP) on the day of discharge. The summary is meant as a communication tool for patients and to expedite information transfer to FPs, not as a substitute for hospital discharge summaries. (4) Early post-discharge followup with the FP, scheduled around the convenience of the patient / iCG. (5) Nurse-led home-care and multi-disciplinary HF clinic referrals for patients deemed to be at high risk of readmission. The risk stratification will be based on a validated risk assessment tool that predicts 30-day readmissions in patients with HF. Within 3 days of discharge, a Community Care Access Center (CCAC) nurse will initiate home transitional care, guided by our standardized, pilot-tested protocol. The CCAC nurse will verify that patients have seen their FP before the end of the month-long home-care period and in the event of clinical deterioration, will guide the patient in following their discharge action plan. Patients referred to their regional HF clinic will be seen as soon as feasible, ideally within a month of discharge.
PERFORMANCE MEASURES
To assess and improve the fidelity of our intervention, we will audit the following process-of-care indicators during routine intervals at each site and provide feedback to 7 partnering institutions: (1) % of patients admitted with HF who receive our intervention; (2) % of discharges in which a written discharge summary is transferred to the FP within a business day of discharge; (3) % of discharged patients who attend a follow-up FP visit within 1 week; (4) % of patients referred for home care who receive a visit within 72 hours of discharge; and (5) % of patients referred to HF clinics who are seen within a month.
OUTCOMES 1.6.1 Primary Outcomes (1)
Time to first event of composite all-cause death, readmission, or Emergency Department (ED) visit within 3 months of an index HF discharge at a participating hospital. An index HF discharge will be defined as an episode in which a patient was discharged alive with the most responsible diagnosis of HF (based on discharge diagnosis [ICD-10] coding); this is concordant with the definition used by MOHLTC. 9 (2) Time to first event of composite all-cause readmission, or ED visit within 30 days of an index HF discharge from a participating hospital. This is of interest to decision makers. We will also report number of events during each time period.
Secondary Outcomes (1)
Patient Discharge Preparedness, as measured by the validated 11-item B-PREPARED telephone survey instrument.
10 (2) Care Transitions Quality, as measured by the 3-item CTM-3 score, administered 6 weeks after the patientÕs discharge. (3) Quality of Life, as measured by the validated EQ5D5L instrument 17 on admission, and after index discharge (at 6 weeks and at 6 months). (4) Health system costs. This will include: (i) total cost of the index hospitalization and all-cause ED visits or readmissions at 6 months of index discharge, (ii) cost of the PACT-HF intervention, and (iii) cost of outpatient follow-up in Ontario at 6 months of index discharge. Cost of index hospitalization, ED visits, and readmissions will include all costs incurred during the episode of care (including direct and indirect hospital costs and physician reimbursement). Cost of PACT-HF will include total cost of personnel and materials required to deliver the hospital, home, and clinic components of the PACT-HF model. Cost of follow-up will include total physician reimbursement and estimated HF clinic costs within 6 months of discharge. Cost-utility will also be determined.
2.0
DATA ACCESS Data will be sourced from administrative databases that are linked to each other and to hospital data via common encrypted identifiers. We will use the following databases for clinical outcomes of patients: (1) Hospital Integrated Decision Support Business Intelligence (IDS-BI) and (2) Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD), both of which contain details about hospital admissions, including dates of admission, demographics, coexisting illnesses, in-hospital treatments, in-hospital mortality, and discharge diagnosis; (3) National Ambulatory Care Reporting System (NACRS), which archives details about ED visits; (4) Ontario Registered Persons Database (ORPD), which archives vital statistics. Information regarding cost outcomes will be derived from: (1) Hospital Case Costing Databases (which record all hospital costs accumulated during the index hospitalization and during ED visits or readmissions within 6 months of discharge); (2) PACT-HF budget data (which includes nurse salary and materials required to deliver the intervention); (3) CCAC Case Costing data (which includes costs of home-care); (4) HF Clinic Case Costing data; and (4) the OHIP database (which includes physician reimbursement). Patient characteristics. Characteristics of each patient discharged alive with a primary diagnosis of HF will be obtained from all hospitals (1) at baseline and (2) following implementation (every month that PACT-HF is introduced to a new hospital). Data will include demographics, comorbidities, invasive / surgical procedures, length of stay, and PACT 
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Version 2015-05-01 8 complications during hospitalization. Data sources: IDS-BI database. Performance measures. Process-of-care measures will be obtained from all hospitals. The plan is to obtain these in the 1 st , 3 rd , 6 th , and last month of the intervention by a NCM and/or research assistant, using data in hospital administrative lists, case report forms, phone calls to the FPs, and records from CCAC. Clinical outcomes. We will measure the time to first 3-month and 30-day composite clinical outcome across all hospitals (1) at baseline (for 1 preceding start of intervention phase) and (2) at each step (i.e. each month that PACT-HF is introduced to a new hospital. Data sources: IDS-BI, CIHI-DAD, NACRS, ORPD databases. Patient-centered outcomes. We will measure Discharge Preparedness, Care Transitions Quality, QOL as measured by EQ5D5L scale. The B-PREPARED, and CTM-3, surveys will be administered to patients 6 weeks after hospital discharge, and EQ-5D-5L scores will be administered during the index admission and 6 weeks and 6 months following discharge. A research assistant who is not involved in providing care to patients, and who is blinded to the study question and intervention will conduct the surveys. Cost outcomes. Information regarding costs will be derived from: (1) Hospital Case Costing Databases (which record all hospital costs accumulated during the index hospitalization and during ED visits or readmissions within 6 months of discharge); (2) PACT-HF budget data (which includes nurse salary and materials required to deliver the intervention); (3) CCAC Case Costing data (which includes costs of home-care); (4) HF Clinic Case Costing data; and (4) OHIP database (which includes in-and out-patient physician costs). Data linkages will be obtained through the Institute of Clinical Evaluative Sciences (ICES) and through MOHLTC.
DATA TRANSFER, ENCRYPTION, AND STORAGE
Patient health card numbers will be transferred to ICES using a secure, encrypted channel established by ICES and managed by authorized ICES individuals.
Authorized ICES individuals will de-identify the data upon receipt. If health card numbers are not available, other information such as hospital numbers, age, sex, and/or postal code will be compared with information in other databases for the purposes of assigning the correct ICES identifier, and once assigned, all identifiers will be removed. The ICES identifier will be used for the purposes of data linkage. Specifically, a Secure Sockets Layer Virtual Private Network (SSL VPN) will be used, which has a high standard of encryption (128 bit or higher) and requires user authentication. Only de-identified data will be used to conduct analyses. Access to data will be limited to authorized individuals (i.e., project members) and subject to prior approval by ICESÕ privacy office. ICES will retain a backup copy of the original, unlinked data on a secure server vault for disaster recovery purposes. The de-identified data, used for analysis, will be stored on a secure ICES server, located in a restricted area within ICESÕ locked and 24/7 video-monitored facility. Data will only be accessed internally, through a password-protected user account. Individuallevel data cannot be removed from this server; only aggregate data such as tabular results may be removed in accordance with ICES policy. Project data will be retained as long as necessary to fulfill the purpose, or in accordance with any contractually specified timeframe.
3.0
ANALYTIC PLAN We will analyze all outcomes using intention-to-treat principle. All statistical tests will be 2-tailed, with alpha = 0.05. We will use SAS 9.2 (Cary, NC) for analyses. At each step, we will compare the following outcomes in the hospitals receiving the intervention with those in hospitals receiving usual care. Primary Outcomes Time to first event of (1) 3 month all-cause death, readmission or ED visit. (2) 30 days composite readmission or ED visit. Additional clinical outcomes will include: number of all-cause readmissions, ED visits, and deaths at 3 months and at 30 days. The analysis for the primary outcomes will be time to first event of the composite outcome using a shared frailty survival model with hospital as random-effects and steps as fixed-effects. We will assess the proportional hazard assumption of the Cox survival 9 model using the global test. If the proportional assumption is violated, we will use the logistic mixed model. The intervention for the primary outcomes will be measured as the hazard ratio for survival or odds ratio for logistic with a 95% confidence interval and a p-value Secondary Outcomes (1) Discharge Preparedness, Care Transitions Measure, and QOL, as measured by the mean B-PREPARED, mean CTM-3, and mean change in EQ-5D-5L scores, respectively. QALY will also be measured. QALY will be calculated using the area under the curve method over the 6-month period. The QALY gained will be compared between the treatments after adjusting for any imbalance in health utility at baseline. The incremental cost per QALY gained will be the summary measure for the economic evaluation. Uncertainty will be expressed using cost effectiveness acceptability curve through non-parametric bootstrapping technique. (2) Health care cost, as measured by the 6-month mean medical cost per patient. We will calculate costs from the perspective of the MOHLTC. In general, relevant health care resources will include those utilized for delivering the intervention and those utilized during the 6 months after discharge. Specifically we will estimate: (i) hospital costs (for index hospitalization, readmissions, and ED visits), (ii) intervention costs (hospital nurse case manager, home-care personnel, and materials), and (iii) outpatient physician visits. Each category (average cost per patient) will be individually analyzed and a total average cost per patient will be provided. Because follow-up for each patient will not exceed a year no discounting will be required. Missing data will be replaced by the mean cost of the missing item. Multiple imputation techniques will be applied to reflect any uncertainties in estimates due to imputed costs.
SAMPLE SIZE / STATISTICAL POWER.
We will assume a 5% type I error rate (twosided) for all calculations. Primary outcomes: 3 month composite of all cause death, readmission and ED visit.. Given ICC of 0.01, a minimum of 10 steps, 5% significance, a study assuming with 3200 index HF patients overall (i.e. 320 index HF patients per hospital for a duration of 11 months (11 steps) based on the assumption of 320 index HF patients per hospital per year) will have 80% power to detect a relative risk reduction of 25% based on a log-rank test. Secondary outcomes (4 steps): Assuming 350 patients admitted per year at each hospital, measurement across 9, a 65% questionnaire completion rate, a death rate of 4% from discharge to 6 weeks, and additional 10% of death rate from 6 weeks to 6 months, there will be a sample size of 164 per hospital from discharge to 6 weeks and 148 per hospital from 6 weeks to 6 months. 
INTRODUCTION
The statistical analysis plan (SAP) specifies the details of the statistical analysis of PACT-HF trial described in the Clinical Study Protocol (version 6.0, dated 2015-12-02). The SAP is a working document that will be amended as new information becomes available. Approval is provided for the content of the appendices at the time of approval. Appendices may be updated as required during the course of the study without obtaining approval for the changes; however the author will inform those approving this document of updates to the appendices. The final version of the SAP will be signed off prior to database lock.
Heart failure (HF) is the most common cause of hospitalization in older adults. The month after hospital discharge represents a vulnerable period, when patients are at increased risk of death and readmission to hospital. Research has shown that certain discharge-planning services can reduce death and readmissions, but these have not been widely implemented. In this study, we will group evidence-informed discharge-planning services into 'Patient-centered Care Transitions in HF' (PACT-HF), a model of care that will prepare patients with HF for their transition from hospital to home. Through PACT-HF, patients will receive a comprehensive assessment of their health care needs, learn to recognize and manage symptoms of HF, and receive the information and follow-up care titrated to their estimated risk of readmission / death. Follow-up care for high risk patients will include home visits by a nurse clinician and care at a multidisciplinary Heart Function Clinic
We will introduce PACT-HF to 10 Ontario hospitals using a multicenter stepped wedge (SW) cluster RCT in which the intervention will be introduced to hospitals over a number of time periods in a randomized sequence until all hospitals receive it. Hospitals will be the unit of randomization, analysis, and inference. The outcomes will be measured at all hospitals prior to the intervention and whenever a new hospital (ÒstepÓ) receives the intervention. At each step, there will be a comparison of outcomes between the hospitals receiving the intervention and those not receiving it. Once assigned the intervention, a hospital will receive it for the remainder of the study.
STUDY HYPOTHESES/OBJECTIVES
We will compare the outcomes (hierarchically ordered) of patients hospitalized with HF in hospitals receiving PACT-HF to those in hospitals receiving Ôusual careÕ.
We anticipate that patients hospitalized at the sites with PACT-HF will have increased time to readmissions, emergency visits, and deaths after discharge; experience higher quality transitional care, feel more prepared for discharge, and report improved quality of life. We also anticipate that overall, PACT-HF will reduce health system resource uses and costs.
STATISTICAL ANALYSIS PLAN TEMPLATE
POPULATIONS TO BE ANALYZED
Primary and secondary (Cost and cost-effectiveness) outcomes
Main analysis ¥ Intervention group = all patients with HF discharged from participating hospitals during PACT-HF intervention phase (identified through ICES databases) ¥ Control group = all patients with HF discharged from participating hospitals during pre-intervention phase (identified through ICES databases)
Patients discharged alive from the following 10 hospitals with the most responsible diagnosis of heart failure (based on discharge diagnosis 
Sensitivity analysis
¥ Intervention group = patients receiving PACT-HF intervention (identified from PHRI case report forms) ¥ Control group = all patients with HF discharged from participating hospitals during pre-intervention phase (identified through ICES databases)
During the intervention phase, patients hospitalized in the 10 hospitals listed above with a most responsible diagnosis of HF will be identified daily through hospital admission databases and referrals from inpatient providers. Diagnosis of HF will be confirmed by the nurse case manager (NCM) using the validated Boston criteria 5 and/or BNP/NTproBNP levels (which are specific for HF). However, patients who does not have HF as primary diagnosis or die during hospitalization or are transferred to another hospital prior to discharge will be excluded. Patients discharged to long-term care facilities will receive the intervention but will be excluded from home nurse visits.
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Secondary outcome (patient-centered) outcomes
¥ Intervention group = patients receiving PACT-HF intervention (identified from PHRI case report forms in the 8 hospitals) ¥ Control group = all HF patients discharged from participating hospitals (8 hospitals) during pre-intervention phase (identified from PHRI case report forms)
Databases
We will use the following databases to identify health care resource use: Canadian Institute for Health Information-Discharge Abstract Database (CIHI-DAD) for inpatient services; National Ambulatory Care Reporting System (NACRS) for emergency department and outpatient clinics; Ontario Health Insurance Plan (OHIP) for provider billings and laboratory services; Ontario Drug Benefit (ODB) and Assistive Devices Program (ADP) for drugs/devices; Continuing Care Reporting System (CCRS) for longterm and complex continuing care; Home Care Database (HCD) Assessment InstrumentHome Care (RAI-HC); and National Rehabilitation Reporting System (NRS) for rehabilitation. We will identify deaths the Ontario Registered Persons Database (ORPD).
We will obtain socioeconomic status using their neighborhood income at the time of incident hospitalization. Following accepted methods [Stephenson et al, Pediatric Pulm 2011], we will capture neighborhood income by linking postal codes to Statistics Canada census data.
BASELINE CHARACTERISTICS
Baseline characteristics for all study patients Ð the PAC-HF and Ôusual careÕ groupsfrom the 10 hospitals will be obtained via ICES administrative databases to maintain consistency (data for the PACT-HF group but not the Ôusual careÕ group -will also be available on the PHRI CRFs); some variables that may not be available in the administrative databases (e.g. living situations, admission and discharge NT-proBNP or BNP levels, LACE score, EQ5D5L) will be obtained from the PHRI case report forms.
Variables will include demographics, vital signs, laboratory investigations, LV function, medical, comorbidities, medication classes at discharge. Certain variables will be used to calculate the readmission risk score (RRS) and the LACE score.
Continuous variables will be summarized using mean with standard deviation and median with interquartile range and categorical variables will be summarized using count with percentages (refer Table 1 in Appendix B).
The p value to compare between PACT-HF vs Usual Care will be obtained using linear mixed regression models with hospitals as random-effects and steps as fixed-effects.
STUDY FOLLOW-UP TIME
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All efforts will be made to collect complete data for all patients in this study. Patients will be followed to the study end and will complete all required data collection, regardless of their compliance with study medications.
In general, missing values within follow up will be treated as ÔmissingÕ. The analyses will be mainly based on observed values. However, we will also consider using some commonly used imputation methods in sensitivity analysis if there are substantial missing data.
The date of hospital discharge (Day 1) is the reference for all time-related analyses. Follow-up time will be defined as the date of last contact for an individual, or the event date if available. Follow-up time will be collected from ICES.
EFFICACY ANALYSIS
The analyses will be based on the intention to treat principle, i.e. with participants analyzed in the group to which they were randomized. Analysis will be carried out for comparison of PACT-HF vs. Usual Care.
Stepped wedge cluster-randomized trial with repeated cross-sectional samples at one month intervals.
Step duration is one calendar month long. On the 1 st day of each month, a new hospital site begins to deliver the PACT-HF intervention. Outcomes are measured each month across all study sites, with intention to treat analysis; comparisons are made between the intervention wedge and the control wedge at each step. Outcomes are analyzed relative to the hospital discharge date.
Primary Outcomes
The primary outcomes are hierarchically ordered as:
1. Time-to-first event of the composite of all-cause readmissions, Emergency Department (ED) visits, or death at 3 months post discharge 2. Time-to-first event of the composite of readmissions or ED visits at 30 days post discharge
Additional clinical outcomes will include: number of all-cause readmissions, ED visits, and deaths at 3 months and at 30 days.
The analysis for the primary outcomes will be time to first event of the composite outcome using a shared frailty survival model to assess the effectiveness of the PACT-HF intervention with hospital as random-effects and steps as fixed-effects. We will assess the proportional hazard assumption of the Cox survival model using the global test. If the proportional assumption is violated, we will use the logistic mixed model. The intervention for the primary outcomes will be measured as the hazard ratio for survival or odds ratio for logistic with a 95% confidence interval and a p-value (refer to Table 3 in Appendix B). We will report the intra-cluster correlation for the proposed outcomes.
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To control the overall type I error rate at the 5% level for efficacy endpoints, a gatekeeper strategy will be used for sequentially testing multiple endpoints in primary outcomes based on the proposed hierarchical order. The null hypothesis testing the first endpoint requires to be statistically significant at a nominal level of 5% before testing the null hypothesis for the subsequent endpoint until a null hypothesis fails to be rejected. The PACT-HF intervention will be declared effective if it significantly improves any of the primary outcomes compared to the usual care.
Secondary Outcomes -Patient centered outcomes
We will also assess patient-centered outcomes in a substudy of 8 hospitals. During these months, the B-PREPARED and CTM-3 telephone survey will be administered to patients 6 weeks after hospital discharge, and the EQ5D5L will be administered during the index admission and via the telephone 6 weeks and 6 months post-discharge. We will also tabulate the baseline characteristics and the primary outcomes for patients completed vs. not completed patient-centered outcomes.
DEFINITIONS
B-PREPARED
The B-PREPARED telephone survey instrument is a sum of 11 items based on a 3-point Likert Scale, scores ranged from 0 to 22, where higher scores correlate with patient satisfaction and predict freedom from Emergency Department usage.
CTM-3
The Care Transition Measure (CTM-3) is a 3-item measure of patientsÕ perspective on coordination of hospital discharge care. Detailed scoring instructions for CTM-3 can be obtained at www.caretransitions.org.
EQ5D5L
The EQ5D5L is a generic, preference-based instrument which measures health status in 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels: no problem (Level 1), slight problems (Level 2), moderate problems (Level 3), severe problems (Level 4), and extreme problem (Level 5). Respondents are also asked to rate their overall health status on a 0-100 hashmarked, vertical visual analog scale (EQ-VAS) on which 0 represents the worst imaginable health state and 100 represents the best possible imaginable health state. Utility indices for the EQ5D5L at 0 (dead) to 1(full health) can be calculated using the scoring algorithm for Canadians developed by Xie et al (Medical Care 2016).
Quality adjusted Life Years (QALY)
QALY is a life duration weighed by quality of life. It is a measure which combines the effects of health interventions on mortality and morbidity. Utilities are measured at three time points for each patient and the QALY for the PACT-HF and the usual care group will be calculated using the area-under-the-curve approach.
ANALYSES
Each of items/parts and the total score for B-prepared and CTM-3 will be summarized using mean with standard deviation and median with interquartile range. The p value to compare between PACT-HF vs Usual Care will be obtained using linear mixed regression models with hospitals as random-effects and steps as fixed-effects (refer to Table 4 in Appendix B). Count data will be analyzed using Poisson regression with the stepped wedge design adjustments.
For the EQ5D5L, we will present the proportion of reported level of responses for each dimension. Mean and standard deviation and median and interquartile range of the EQ-VAS and EQ5D5L utility index will be presented as well. The results will be given for each data collection (baseline, at 6 week, and at 6 months) according to the intervention status.
In addition, we will analyze EQ5D5L utility index and EQVAS using linear mixed regressions with repeated measures based on the complete dataset. Average changes in each outcomes compared to baseline will be compared between PACT-HF vs. usual care.
The treatment effect on QALY will be assessed using mixed linear regression model with baseline utility and other relevant covariates included as independent variables. Some commonly used imputation methods will be considered in sensitivity analysis if there are missing data.
Secondary Outcomes -Costs and cost-effectiveness
We will conduct the analyses on the total cost (derived from ICES) for all 10 hospitals including home care, readmissions to acute inpatient care, emergency department and outpatient, complex continuing care (CCC), physician services, inpatient rehabilitation and long-term care within 6 months of discharge 6 .
We will tabulate costs from the perspective of the provincial Ministry of Health and Long Term Care (MOHLTC), using person-level health care expenditures. We will obtain records of health care use paid for by the MOHLTC, following the definitions above. The cost associated with each record will be estimated using costing methods developed for health administrative data [Wodchis et al. HSPRN 2013] . Cost information for sectors / institutions that have global budgets will be determined through case-mix methodology. Sectors that have fee payments associated with each use (e.g., drug cost, or physician billing) will have costs estimated directly. Home care expenditures will be calculated as actual total billing charges per patient based on services used during total length of stay (LOS) in home care program from date of initiation until discharge from home care (entire home care episode) (table 1). All costs will be expressed in 2016 Canadian dollars, with inflation of past costs using healthcare specific yearly Consumer Price Index reported by Statistics Canada. Health sector cost for the population is the sum of all costs among decedents captured within each respective sector. We will also examine total cost for patients received PACT-HF vs. Òusual careÓ using mean with standard deviation and median with interquartile range. We will assess the normality assumption of the cost. If
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Cost effectiveness analysis will be conducted by calculating incremental cost per readmission/death averted between the PACT-HF and the usual care groups. Cost-utility analysis will be conducted by calculating incremental cost per QALY gained by the PACT-HF group versus the usual care group. The 95% confidence intervals around the two ratios will be identified using non-parametric bootstrapping approach. Cost effectiveness acceptability curve will be used to present the probability of the PACT-HF being the cost effective strategy over a wide range of maximum willingness to pay value.
SENSITIVITY ANALYSIS
COMPETING RISK
We will repeat the analyses for the primary composite outcomes where the death will be treated as a competing risk.
MISSING DATA
We will repeat the analyses for the patient-centered outcomes where the missing outcomes will be imputed using the multiple imputation or other relevant imputation techniques.
APPLIED HEALTH RESEARCH QUESTION: A RISK PREDICTION MODEL FOR 30-DAY READMISSION AND DEATH
A related question is whether LACE combined with deltaBNP and/or other variables can independently predict the 30 day composite outcome of readmission and death to improve calibration and discrimination. The analyzed population will be limited to patients received PACT-HF. Other potential predictors that we are interested are the baseline characteristics and also baseline EQ5D5L utility and EQ VAS score.
We will first run the univariate analyses for the potential variables as independent variables and the 30-day composite outcome as dependent variable using linear/logistic mixed models adjusted for patients received transitional care as covariate and stepped wedge design with hospitals as random-effects and steps as fixed effects (refer to Table 7 in Appendix B). Patients received transitional care are those who receive home nursing and those who receive heart function clinic care. The aim is to test if they are the predictors of the 30-day composite outcome. The variables with a p<0.2 in the univariate analyses will be retained to be assessed in the following models. We will follow the purposeful method for model building.
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Next, we will run the models (refer Table 8 in Appendix B) and compute Cstatistic(95%CI) and NRI(95%CI) for each model.
APPENDIX A. DEFINITIONS
Patients will be assigned to the ÔUsual CareÕ group if their discharge date of the index hospitalization (1 st hospitalization during study period) is before the intervention start date for the hospital. Patients will be assigned to the PACT-HF group if their discharge date is during the intervention phase of the hospital (between the intervention start date and Feb 29, 2016). For instance, patients in site#9 with a discharge date before March 1, 2015 are considered in Usual Care, otherwise they are considered in PACT-HF. Steps are labelled 1 to 11, corresponding to calendar months of the year
Step 1 = Feb 2015 (control month for PACT-HF intervention)
Step 2 = March 2015 (Beginning of intervention phase)
Step 3 = April 2015 (control month for questionnaire substudy)
Step 4 = May 2015
Step 5 = June 2015
Step 6 = July 2015
Step 7 = August 2015
Step 8 = September 2015
Step 9 = October 2015
Step 10 = November 2015
Step 11 = December 2015, Jan 2016, Feb 2016 LACE score 4 includes the length of hospitalization stay (ÒLÓ), acuity of the admission (ÒAÓ), comorbidities of patients (ÒCÓ), and emergency department use of patients (ÒEÓ). We also included the following clinical outcomes excluding deaths 1) Number of all-cause readmissions, ED visits in 30 days 2) Number of all-cause readmissions, ED visits in 3 months
PACT-HF SUMMARY OF PROTOCOL CHANGES
RATIONALE FOR PROTOCOL CHANGES
We changed the primary outcomes within 2 months of PACT-HF trial initiation to include endpoints that were 1) clinically relevant to health care resource utilization, 2) using time points that were more applicable to transitional care interventions, and 3) using time-to-event rather than count analysis.
For example, we felt that that 3-month outcomes were more likely than 6 month outcomes to be linked with the quality of transitional care services occurring immediately following discharge; and that 6 month clinical outcomes were likely to be influenced by factors other than transitional care services.
Furthermore, it is known that only 25-30% of patients have readmissions or ED visits within 30 days of hospitalization for HF (i.e. 70-75% of patients have 0 count outcomes); our concern was that modeling count data for outcomes would lead to biased and inefficient estimates, which is why we selected time-to-event outcomes for the primary analysis. However, we included count data among the clinical outcomes. The analysis in the protocol changed accordingly.
It should be noted that outcomes of PACT-HF were determined through linkages with provincial databases, not through prospective follow-up of patients. There is a 1.5 to 2 year lag period between the end of PACT-HF and the accessibility of clinical and cost outcomes via provincial databases due to delays in updating the databases, cleaning the data, and updates in macros. We did not have access to PACT-HF outcomes in the 2 month period between start of the trial and the updated protocol, minimizing the risk of bias. Hospitals cross over from usual care to intervention in a randomized sequence. Outcomes are measured at participating hospitals the month prior to the intervention phase and whenever a new hospital ("step") receives the intervention. At each step, outcomes are measured at all hospital sites and there is a comparison of outcomes between the hospitals receiving the intervention (intervention wedge) and hospitals not to receiving it (control wedge); thus comparisons are made both within and between clusters at each step. There are 10 hospital sites, 11 steps, 55 usual care crosssections, and 55 intervention cross-sections. There is a one-month interval between steps. The clear cells represent the usual care wedge and the shaded cells represent the intervention wedge. The cells within bolded borders sites depict hospitals collecting the patient-centered outcomes. There are 11*10 = 110 measurements for the clinical and cost outcomes and 9*8 = 72 measurements for the patient-centered outcomes.
Site
Step ( 
